There are many publications where PharmaPendium was used to do cutting edge research. You will find a selection of recent publications below. Information on how to cite PharmaPendium can be found here

Use of Patient Health Records to Quantify Drug- ll ll Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk. Davies, M. R., Martinec, M., Walls, R., Lave, T., Singer, T., Polonchuk, L., Davies, M. R., Martinec, M., Walls, R., Schwarz, R., Mirams, G. R., Wang, K., Steiner, G., Surinach, A., Flores, C., Lave, T., Singer, T., Liudmila, P. (2020). Cell Reports Medicine 1 (5),  100076  Article / DOI Researchers at Roche have used the PharmaPendium FAERS database to evaluate post-market reports from 2000 till 2015 for reports on Cardiac Arrythmias. They found a reduced but still significant number of drugs can still induce cardiac Arrythmias and argue for better in silico prediction and post-market analysis.

Industrial Approach to Determine the Relative Contribution of Seven Major UGT Isoforms to Hepatic Glucuronidation. Busse, D., Leandersson, S., Amberntsson, S., Darnell, M., & Hilgendorf, C. (2020). Journal of pharmaceutical sciences, 109(7), 2309–2320 Article / Embase / DOI . Medicinal chemists are getting better in designing drugs that are metabolically stable and are not processed by CYP enzyme. Consequently, other pathways like UGT-metabolism are getting increasingly in focus. To anticipate drug-drug interactions, it is crucial to translate invitro activity of UGT enzymes (liver microsomes or recombinant) to in vivo clinically activity and know the relative contribution of UGT enzyme isoforms. This can be done by establishing relative activity factors (RAF) that scale single enzyme activity to organ level. Researchers from AstraZeneca have now developed a RAF for a set of UGT enzyme isoforms They have used PharmaPendium to analyze EMA and FDA regulatory Documents for the relative abundance of UGT enzyme isoform data. This data could effectively be retrieved using PharmaPendium’s extracted metabolizing enzyme and transporter data and enzyme taxonomies.

Freshly isolated primary human proximal tubule cells as an in vitro model for the detection of renal tubular toxicity. Bajaj, P., Chung, G., Pye, K., Yukawa, T., Imanishi, A., Takai, Y., Brown, C., & Wagoner, M. P. (2020). Toxicology Article / Embase / DOI Many drugs and drug metabolites have toxic effects on kidney cells thereby causing Drug induced kidney injury (DIKI). Currently animal models for DIKI suffer from low sensitivity, so quite a bit of DIKI goes undetected early in drug development. This results in late stage failure and the need for better preclinical in vitro models. In this paper, researchers from Pharma company Takeda develop a new cell model for early detection of DIKI using freshly isolated primary human kidney cells. The authors test the sensitivity of their system with a panel of clinical nephrotoxic and non-nephrotoxic drugs. Relevant Drugs for sensitivity testing were identified using PharmaPendium’s clinical drug safety data manually excerpted from regulatory document as well as PharmaPendium’s expert adverse events taxonomy. 

Hepatic Transcript Profiles of Cytochrome P450 Genes Predict Sex Differences in Drug Metabolism. Fuscoe, J. C., Vijay, V., Hanig, J. P., Han, T., Ren, L., Greenhaw, J. J., Beger, R. D., Pence,  L. M.,  Shi, Q. (2020). Drug Metabolism and Disposition (In press) Article / Embase /DOI  
Gender diffrences could have significant impact on drug metabolism and the drug safety profile. Sex-associated susceptibilities are often not adequately addressed, and better tools are needed. The FDA researchers found that sex-different expression of genes coding for drug metabolizing enzymes could be used to predict sex-different drug metabolism. The FDA researchers used PharmaPendium's Metabolizing enzyme and transporter data to indentify associations between drugs and drug metabolizing enzymes.

A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS). Rees, K. E., Chyou, T., & Nishtala, P. S. (2020). Drug Safety Article / Embase / DOI
FDA Adverse event reporting system (FAERS) data is a critical resource to monitor the post-market risk benefit analysis of marketed drugs. The FAERS database is included in PharmaPendium and is enhanced with filters, adverse events table and comprative visualizations. Using PharmaPendium FAERS data the group of Prof. Nishtala evaluated adverse events associated with lurasidone, a second-generation antipsychotic used in the treatment of schizophrenia and bipolar disorder

Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse events. Paglialunga, S., Morimoto, B. H., Clark, M., Friedrichs, G. S. (2019). Journal of Pharmacological and Toxicological Methods, 99. Article / Embase / DOI
In this publication, extracted PharmaPendium drug safety data was used to evaluate the predictive value of preclinical respiratory observations for clinical respiratory adverse events. The authors found that the translatability of preclinical respiratory findings into clinical adverse events is low and suggests that the mandating of dedicated respiratory SP studies as part of the core battery should be reconsidered

Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro. Amouzadeh, H. R., Dimery, I., Werner, J., Ngarmchamnanrith, G., Engwall, M. J., Vargas, H. M., & Arrindell, D. (2019). Translational Oncology, 12(10) 1296–1304, Article / Embase / DOI
Pharmapendium was used to effectively access preclinical and clinical drug safety data, extracted from approval packages, for drugs that have been marketed to inhibit adenosine transporter or affect adenosine receptors. This allowed the authors to compare the safety profile of their drug of interest with marketed drug acting on the same target.

Qualification of Impurities Based on Metabolite Data. Weidolf, L., Andersson, T., Bercu, J. P., Brink, A., Glowienke, S., Harvey, J., Hayes, M. A., Jacques, P., Lu, C., Manevski, N., Muster, W., Nudelman, R., Ogilvie, R., Ottosson, J., Trela, B. (2019). Regulatory Toxicology and Pharmacology, 104524. Article /  Embase / DOI

A Framework Proposal to Follow-Up on Preclinical Convulsive Signals of a New Molecular Entity in First-in-Human Studies Using Electroencephalographic Monitoring. Abt, M., Dinklo, T., Rothfuss, A., Husar, E., Dannecker, R., Kallivroussis, K., Peck, R. Doessegger L., Wandel, C. (2019). Clinical Pharmacology and Therapeutics, 106(5), 968–980. Article / Embase / DOI

Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations. Lyauk, Y. K., Jonker, D. M., & Lund, T. M. (2019). Clinical and Translational Science, 12(5), 481–489. Article / Embase / DOI